Back to search

Peptide record

TPDB13462

Antibacterial Toxicity standard
25 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13462
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia
standard
No
A 25-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KFKKLFKKLSPVFKRIVQRIKDFLR
Physicochemical Analysis
C153H256N42O30
ANCEGHMTWY
K
3163.98
12.19
10
1
11
+9
5.07
-0.408
101.20
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
0
A
3
R
0
N
1
D
0
C
0
E
1
Q
0
G
0
H
2
I
3
L
7
K
0
M
4
F
1
P
1
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 1 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 2 L: 3 K: 7 M: 0 F: 4 P: 1 S: 1 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
25
C153H256N42O30
3163.98
12.19
+9
5.07
-0.408
Evidence Records 4 records
Evidence 1 Activity

Activity

18% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
18% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of a new hybrid peptide from LL-37 and BMAP-27. | Infect Drug Resist | 2019
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
50% Hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design and characterization of a new hybrid peptide from LL-37 and BMAP-27. | Infect Drug Resist | 2019
Evidence 3 Activity

Activity

IC50
Toxicity
23.4 µM
Cytotoxic
IC50 | 23.4 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Design and characterization of a new hybrid peptide from LL-37 and BMAP-27. | Infect Drug Resist | 2019
Evidence 4 Activity

Activity

% Hemolysis
Toxicity
0 %
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.31118709] 0% hemolysis at 10µM, 8% hemolysis at 25µM, 19% hemolysis at 50µM, 23% hemolysis at 75µM, 30% hemolysis at 100µM, 38% hemolysis at 125µM, 40% hemolysis at 150µM, 43% hemolysis at 175µM, 50% hemolysis at 200µM against human blood cells. | Cytotoxicity: [Ref.31118709] The cell viability of HEK293 mammalian cell line induced by B1 is 87.0%, 67.1%, 52.3%, 54.3%, 50.6% and 50% at peptide concentrations of 10, 20, 40, 60, 80 and 100 µM.

Target

erythrocytes

Source & Reference

NA
DRAMP
Infect Drug Resist. 2019 12: 1035–1045. Published online 2019 Apr 30. doi: 10.2147/IDR.S199473